Patents by Inventor Joaquina Mascarenhas

Joaquina Mascarenhas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE TARGETED INTEGRATION
    Publication number: 20220195465
    Abstract: Methods for integrating exogenous sequences in genomic loci, wherein the integration is stable and the exogenous sequence can function predictably and reliably.
    Type: Application
    Filed: April 20, 2020
    Publication date: June 23, 2022
    Inventors: Scott Bahr, Michael Johns, James Ravellette, Joaquina Mascarenhas, Trissa Borgschulte
  • ENGINEERED CELLS WITH MODIFIED HOST CELL PROTEIN PROFILES
    Publication number: 20210238628
    Abstract: Mammalian cell lines genetically engineered to have reduced or eliminated expression of specific host cell proteins, and methods for using the engineered mammalian cell lines for the production of recombinant proteins having low levels of residual host cell protein contamination.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 5, 2021
    Inventors: Joaquina Mascarenhas, Trissa Borgschulte, Kevin Kayser
  • PRODUCING RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS
    Publication number: 20210238222
    Abstract: Processes for producing recombinant proteins having low levels of residual host cell proteins. The processes comprise utilizing engineered host cell lines in which specific host cell proteins are tagged with purification tags, wherein the purification tags can be used to remove those specific host cell proteins from the recombinant proteins.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 5, 2021
    Inventors: Trissa Borgschulte, Joaquina Mascarenhas, Martin Zillmann, Frank Swartzwelder, Kevin Kayser
  • VIRAL RESISTANT CELLS AND CULTURE SYSTEMS
    Publication number: 20190390241
    Abstract: Mammalian cell lines genetically engineered to be viral resistant, cell culture systems comprising agents that inhibit viral entry into or translocation within cells, and methods of using said cell lines and/or said cell culture systems to reduce or prevent viral contamination of biologic production systems.
    Type: Application
    Filed: January 24, 2018
    Publication date: December 26, 2019
    Inventors: Joaquina Mascarenhas, Audrey Chang, Nikolay Korokhov, David Onions, Henry George, Kevin J. Kayser
  • Viral resistant cells and uses thereof
    Patent number: 10377990
    Abstract: The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: August 13, 2019
    Assignee: SIgma-Aldrich Co. LLC
    Inventors: Nan Lin, Joaquina Mascarenhas, Audrey Chang, David Onions, Henry George, Kevin Kayser
  • VIRAL RESISTANT CELLS AND USES THEREOF
    Publication number: 20160369240
    Abstract: The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.
    Type: Application
    Filed: March 3, 2015
    Publication date: December 22, 2016
    Inventors: Nan LIN, Joaquina MASCARENHAS, Audrey CHANG, David ONIONS, Henry GEORGE, Kevin KAYSER
  • Method of producing human-like glycosylation pattern using cells deficient in glutamine synthase, CMP-N-acetylneuraminic acid hydroxylase and/or glycoprotein alpha-1,3-galactosyltransferase
    Patent number: 9062338
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 23, 2015
    Assignee: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • CELLS DEFICIENT IN CMP-N-ACETYLNEURAMINIC ACID HYDROXYLASE AND/OR GLYCOPROTEIN ALPHA-1,3-GALACTOSYLTRANSFERASE
    Publication number: 20150152463
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 4, 2015
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • Cells deficient in CMP-N-acetylneuraminic acid hydroxylase and/or glycoprotein alpha-1,3-galactosyltransferase
    Patent number: 8980583
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 17, 2015
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
  • CELLS DEFICIENT IN CMP-N-ACETYLNEURAMINIC ACID HYDROXYLASE AND/OR GLYCOPROTEIN ALPHA-1,3-GALACTOSYLTRANSFERASE
    Publication number: 20130004992
    Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien